Gongwin Biopharm Holdings Co., Ltd. (TPEX: 6617)
Taiwan
· Delayed Price · Currency is TWD 113.50
-1.50 (-1.30%)
Dec 2, 2024, 10:11 AM CST
Gongwin Biopharm Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 31.76 | 18.92 | 1.14 | 1.14 | 0.83 | 0.25 | Upgrade
|
| Revenue Growth (YoY) | 178.39% | 1554.86% | 0% | 37.21% | 235.89% | 300.00% | Upgrade
|
| Cost of Revenue | 13.79 | 7.72 | 0.08 | 0.07 | 0.05 | 0.01 | Upgrade
|
| Gross Profit | 17.97 | 11.2 | 1.07 | 1.08 | 0.79 | 0.23 | Upgrade
|
| Selling, General & Admin | 104.64 | 91.88 | 67.43 | 38.85 | 41.89 | 46.54 | Upgrade
|
| Research & Development | 61.8 | 52.65 | 194.32 | 83.05 | 76.26 | 82.52 | Upgrade
|
| Operating Expenses | 169.82 | 144.53 | 261.75 | 121.9 | 118.15 | 129.06 | Upgrade
|
| Operating Income | -151.85 | -133.33 | -260.68 | -120.83 | -117.37 | -128.82 | Upgrade
|
| Interest Expense | -4.11 | -7.19 | -3.19 | -1.18 | -0.5 | -1.4 | Upgrade
|
| Interest & Investment Income | 53.66 | 41.61 | 6.82 | 2.4 | 4.6 | 12.57 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.05 | -4.85 | -39.6 | 0.9 | 5.87 | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.51 | 2.58 | 4.51 | 2.05 | 1.53 | 1.29 | Upgrade
|
| EBT Excluding Unusual Items | -100.75 | -101.18 | -292.13 | -116.66 | -105.87 | -116.3 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.74 | 4.68 | 0.98 | Upgrade
|
| Other Unusual Items | - | - | - | 1.2 | 1.87 | - | Upgrade
|
| Pretax Income | -100.75 | -101.18 | -292.13 | -114.72 | -99.32 | -115.32 | Upgrade
|
| Income Tax Expense | 0.12 | - | - | 15.2 | - | - | Upgrade
|
| Earnings From Continuing Operations | -100.87 | -101.18 | -292.13 | -129.92 | -99.32 | -115.32 | Upgrade
|
| Minority Interest in Earnings | -2.09 | - | - | 8.34 | 6.25 | 5.5 | Upgrade
|
| Net Income | -102.96 | -101.18 | -292.13 | -121.58 | -93.07 | -109.82 | Upgrade
|
| Net Income to Common | -102.96 | -101.18 | -292.13 | -121.58 | -93.07 | -109.82 | Upgrade
|
| Shares Outstanding (Basic) | 118 | 113 | 111 | 110 | 104 | 103 | Upgrade
|
| Shares Outstanding (Diluted) | 118 | 113 | 111 | 110 | 104 | 103 | Upgrade
|
| Shares Change (YoY) | 3.98% | 1.92% | 1.44% | 4.87% | 1.37% | 2.13% | Upgrade
|
| EPS (Basic) | -0.87 | -0.89 | -2.63 | -1.11 | -0.89 | -1.07 | Upgrade
|
| EPS (Diluted) | -0.88 | -0.89 | -2.63 | -1.11 | -0.89 | -1.07 | Upgrade
|
| Free Cash Flow | -281.38 | -111.7 | -239.54 | -218.52 | -117.4 | -107.45 | Upgrade
|
| Free Cash Flow Per Share | -2.39 | -0.99 | -2.16 | -1.99 | -1.12 | -1.04 | Upgrade
|
| Gross Margin | 56.58% | 59.21% | 93.26% | 94.31% | 94.36% | 94.35% | Upgrade
|
| Operating Margin | -478.06% | -704.87% | -22806.74% | -10570.95% | -14089.56% | -51944.76% | Upgrade
|
| Profit Margin | -324.15% | -534.89% | -25558.44% | -10637.01% | -11173.11% | -44283.87% | Upgrade
|
| Free Cash Flow Margin | -885.86% | -590.55% | -20956.69% | -19118.11% | -14093.16% | -43327.42% | Upgrade
|
| EBITDA | -141.33 | -125.03 | -252.2 | -112.82 | -110.64 | -123.17 | Upgrade
|
| D&A For EBITDA | 10.52 | 8.29 | 8.48 | 8 | 6.72 | 5.65 | Upgrade
|
| EBIT | -151.85 | -133.33 | -260.68 | -120.83 | -117.37 | -128.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.